A case report of exacerbation of extrapyramidal symptoms following the switch from risperidone to paliperidone during valproate therapy
Abstract Background Paliperidone is a second-generation antipsychotic and the main active metabolite of risperidone, formulated to provide consistent therapeutic effects through an extended-release system, designed to provide consistent therapeutic effects through an extended-release formulation. Wh...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Psychiatry |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12888-024-06456-x |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|